Xalatamax, eye drops 0.005% 2.5ml 3 pcs

Antiglaucoma drug for topical use. Latanoprost is an analogue of prostaglandin F_2α and a selective agonist of FP-receptors.

Latanoprost reduces intraocular pressure by increasing outflow of aqueous humor and has anti-glaucoma effect. The main mechanism of action of latanoprost is related to the increase of uveoscleral outflow.

It has no reliable effect on aqueous humor production and does not affect the heme-ophthalmic barrier.

The decrease of intraocular pressure starts 3-4 hours after administration of the drug with maximal effect noted after 8-12 hours and the duration of action at least 24 hours.

Indications

Active ingredient

Composition

Active substance:

Latanoprost – 0.050 mg.

Auxiliary substances:

benzalkonium chloride, 0.20 mg;

sodium dihydrophosphate monohydrate, 4.60 mg;

p> sodium hydrophosphate – 4.74 mg;

sodium chloride – 4.10 mg;

purified water – 996.31 mg.

How to take, the dosage

The drug is injected into the conjunctival sac of the eyes 1 drop once a day in the evening.

If a dose is missed, the next dose is given as usual (i.e., the dose is not doubled).

If the drug is administered more frequently, its effectiveness is reduced.

The duration of treatment and whether it can be repeated is determined by the doctor.

Interaction

Latanoprost has an additive effect in lowering intraocular pressure when used in combination with beta-adrenoblockers, adrenomimetics, carboenhydrase inhibitors and a partial additive effect when used in combination with m-cholinomimetics.

In vitro studies have EXPECTED that precipitation occurs when eye drops containing thiomersal are mixed with latanoprost. Therefore, eye drops containing these substances should be used at least 5 min apart. Simultaneous use of 2 prostaglandin analogues may cause a paradoxical increase in intraocular pressure.

Special Instructions

Latanoprost can cause a gradual change in eye color by increasing the amount of brown pigment in the iris.

This effect is mainly seen in patients with mixed iris coloration such as blue-brown, gray-brown, green-brown, or yellow-brown due to increased melanin content in the stromal melanocytes of the iris.

Brown pigmentation usually spreads concentrically around the pupil to the periphery of the iris, and the entire iris or parts of the iris may become more intense brown. In patients with evenly colored blue, gray, green, or brown eyes, changes in eye color were very rare after two years of use.

The color change is not accompanied by any clinical symptoms or pathological changes.

There has been no further increase in brown pigment after discontinuation of the drug, but the color change that has already developed may be irreversible. In the presence of nevi or lentigotes on the iris, no change was observed under the influence of therapy.

Synopsis

Contraindications

Side effects

Visual side:

. Eye irritation (burning sensation, sensation of sand in the eye, itching, tingling and sensation of foreign body), blepharitis, conjunctival hyperemia, eye pain, increased iris pigmentation, Transient pinpoint epithelial erosions, eyelid edema, corneal edema and erosions, conjunctivitis, lengthening, thickening, increased number and increased pigmentation of eyelashes and downy hair, iritis/veitis, keratitis, macular edema (including cystoid).including cystoid), changes in lash growth direction, sometimes causing eye irritation, blurred vision.Achor: #Dermatologicheskie_reakcii

Dermatological reactions: Rash, darkening of eyelid skin, and local cutaneous reactions on the eyelid side.

Nervous system disorders: Dizziness headache.

Respiratory system: Bronchial asthma (including acute attacks or exacerbation of the disease in patients with a history of bronchial asthma), dyspnea.

Muscular system disorders: Muscle pain, joint pain.

Others: Non-specific chest pain.

Overdose

Symptoms: irritation of the mucous membrane of the eye, hyperemia of the conjunctiva or episclera.

Treatment: symptomatic therapy is carried out.

Pregnancy use

Similarities